Final Programme. 14 th Conference of the International Society of Geriatric Oncology. "Bringing Two Worlds Together: Oncology and Geriatrics"

Transcription

1 2014 LISBON 14 th Conference of the International Society of Geriatric Oncology

2 JOURNAL OF GERIATRIC ONCOLOGY OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY (SIOG) Editor-in-Chief: Arti Hurria, MD, City of Hope, Duarte, USA The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The Journal of Geriatric Oncology publishes original research articles, review articles, clinical trials, treatment guidelines, short communications and letters to the Editor., MAKE AN IMPACT! Get your research read.! Publishing 6 issues from 2015!! All accepted manuscripts are published online as Articles-in-Press within 4 weeks! Open access publishing options available! Worldwide dissemination through ScienceDirect: more than 19,000 articles downloaded in previous 12 months Submit your paper online at For more information, please visit our website:

3 3 Welcome Message Dear SIOG Colleagues and Friends, Following the great success of the 2013 SIOG Annual Conference in Copenhagen, it is our pleasure to welcome you this time in Lisbon for the 14th Annual Conference of the International Society of Geriatric Oncology. This year's conference celebrates its mission by bringing together multidisciplinary experts in cancer and aging via its annual conference theme, "Bringing Two Worlds Together: Oncology and Geriatrics." The 2014 Programme Committee, Track Leaders and Portuguese experts in the field have been working tirelessly to put together this year s sessions. The focus of these sessions intends to bridge the gap of best practices between geriatrics and oncology featuring multidisciplinary sessions on hard tumours, haem malignancies, new therapies, geriatric assessment, supportive care needs and an educational forum dedicated to nurses. To illustrate this approach, this year s Partnership Session promotes the new SIOG collaboration with the European Geriatric Medicine Society (EUGMS) involved in the planning of this conference and in the development of other SIOG educational on-going projects. The SIOG meeting also includes special sessions in collaboration with industry to present the latest therapeutic data and their application to the older adults. SIOG is also dedicated to the development of new research, of nursing and allied health practice knowledge and of junior faculty with the scheduling of new abstract based award sessions. Planning this meeting has called for year-long dedication from SIOG members who volunteered for leadership positions. They have given selflessly of their time in order to advance the field of geriatric oncology and to share their findings with you. For this we are very grateful. But ultimately the success of this gathering rests with you, your presence, your expertise, your ideas, and your participation. We look forward to exchanging knowledge and best practice with you here in Lisbon! We hope you will enjoy this moment together. Best wishes, Dr. Vesa Kataja Chair, Scientific Programme Dr. Arti Hurria President Dr. Francisco Pimentel SIOG 2014 Scientific Liaison

4 4 Venue Plan Level 1 Level 0

5 5 SIOG 2014 Programme Committee Vesa Kataja, Chair (FI) Arti Hurria, Co-Chair (USA) Francisco Luis Pimentel, Local Scientific Liaison (PT) Matti Aapro, Chair, Corporate Relations Committee (CH) Laurence Verhagen, SIOG Chief Executive Officer (CH) and the following Track Leaders Track 1 Solid Tumours Ajeet Gajra (USA), Hans Wildiers (BE), William Dale (USA), Ana Pais (PT) Track 2 Haem Malignancies Vicki Morrison (USA), Alfonso Cruz-Jentoft (ES), Maria Gomes da Silva (PT) Track 3 New Therapies and Basic Science Claire Falandry (FR), Giampaolo Tortora (IT), Andrea Maier (NL), Berta Sousa (PT), Fatima Cardoso (PT) Track 4 Nursing, Supportive Care & Geriatric Assessment Margot Gosney (GB), Siri Rostoft Kristjansson (NO), Aaron Begue (USA), Edna Gonçalves (PT) Track 5 Advocacy and Socio-Economical Issues Beena Devi (MA), Muriel Rainfray (FR), Lea Baider (IL), Elisabete Valério (PT) SIOG 2014 Reviewers Aaron Begue (USA) Peggy Burhenn (USA) William Dale (USA) Beena Devi (MA) Claire Falandry (FR) Ajeet Gajra (USA) Maria Gomes da Silva (PT) Edna Goncalves (PT) Margot Gosney (GB) Arti Hurria (USA) Alfonso J. Cruz Jentoft (ES) Vesa Kataja (FI) Andrea Maier (NL) Vicki Morrison (USA) Ana Pais (PT) Muriel Rainfray (FR) Siri Rostoft Kristjansson (NO) Berta Sousa (PT) Elisabete Valério (PT) Hans Wildiers (BE)

6 6 Conference venue Lisboa Congress Centre Praça das Indústrias Lisboa - Portugal Tel: +(351) Fax: +(351) lisboacc@aip.pt - Name Badges All participants are requested to wear their name badges throughout the conference. Registration The registration desk will be open at the following hours: n Thursday 23 October 08:00-20:30 n Friday 24 October 07:00-20:30 n Saturday 25 October 07:00-17:00 Registration Fee The registration fee includes: - Opening Address - Access to all scientific sessions - Access to the Posters and scientific Display Area - Access to on-line abstract book (searchable pdf format)supplement of the Journal of Geriatric Oncology, which will be indexed and referenced in PubMed and Science Direct. - Access to conference proceedings after the conference - Conference material - 23% VAT (Value Added Tax) Onsite Registration Cash payment possible at the registration desk in Euro. Credit card payment will be made in Euros. Certificate of Attendance Please complete the attendance form and bring it back to the registration desk starting Friday 24 October 16:00. You will then receive your certificate. SIOG Membership To become a SIOG member, please fill out the on-line membership form directly onto the SIOG website: wwww.siog.org Exhibition Selected pharmaceutical and medical societies have been invited to exhibit their products and services. The exhibition is located in the Foyer of Auditoria 6 and 7 Exhibition Hours n Thursday, 23 October :00-19:30 n Friday 24, October :30-18:00 n Saturday, 25 October :30-15:00 Poster Information Posters will be displayed in the poster areas during the whole duration of the conference in the Exhibition area. Presenting authors are kindly requested to be present at their poster for presentation on: n Thursday, 23 October 2014: 10:30-11:00/12:30-14:00/17:00-17:30 n Friday, 24 October 2014: 10:00-10:30/12:45-14:00/17:00-17:30 n Saturday, 25 October 2014: 10:00-10:30/12:45-13:15 Hanging: n Thursday, 23 October 2014: Dismantling: n Saturday, 25 October 2014: as of 17:30. Posters not removed after 18:30 will be discarded. SIOG Young Investigator Award To promote research in the field of geriatric oncology and support the career development of the new generation of experts, SIOG launches this year the SIOG Young Investigator Award. With the support of SIOG, the winner will receive e1000 with a free registration for 2015 conference and the other 2 selected finalists will receive e500 each with a free registration for the 2015 conference. SIOG Nursing & Allied Health Investigator Award This award aims to recognise significant contributions from new investigators in geriatric oncology nursing and allied professions at international level. With the support of AMGEN, the winner will receive e1000 with a free registration for the 2015 conference and the other 2 selected finalists will receive e500 with a free registration for the 2015 conference. Both awards will be delivered at the SIOG Presidential Session on Saturday 25 October at 09:00. Ecancer Following last year success, e-cancer, the leading oncology channel, will again provide highlights of SIOG 2014 through scientific interviews of our conference experts. Stay tunned when the videos will be made available on SIOG and ecancer websites. Poster Welcome Reception (Poster Area) n Thurday, 23 October 2014: as of 18:30 This scientific and networking event is offered by SIOG to allow all delegates and friends of SIOG to exchange best practices and facilitate collaborations. Lunch & Coffee Breaks All lunches and coffee breaks will be located near the exhibition area in the Foyer of Auditoria 6 and 7. If you have ordered a lunch box in advance, you will receive corresponding vouchers to exchange for a lunch box. SIOG 2014 Dinner On the shores of the Tagus river, close to the Maritime Terminal of Alcantara, this dinner will be held at the Espaço Lisboa. Rua dacozinha Economica, N 16, Lisboa. Meeting point to walk to the venue is at 19:00 in front of the Conference Center. Conference Language The official conference language is English. Messages You may leave and collect messages at the registration desk. Insurance A personal travel insurance policy to cover theft, loss and medical problems is highly recommended. SIOG, SIOG 2014 and MCI Suisse SA as organisers cannot accept to be held liable for any problems caused during the participant s travel and stay at the conference. Wi-Fi WIFI will be available. You can retrieve supplementary information at the Registration Desk Online Abstract Book Delegates of the 2014 SIOG Conference can enjoy complimentary full text access to the Journal of Geriatric Oncology from the first day of the 2014 SIOG Conference, Thursday 23 October until Monday 31 December 2014! For your complimentary access, simply go to elsevierdigital.com/jgo/siog2014 Onsite Abstract Printing Printing of abstracts is possible at the Elsevier printing booth in the exhibition area.

7 7 SIOG 2014 wishes to express its appreciation to GOLD SPONSOR SILVER SPONSOR BRONZE SPONSOR CONFERENCE Supporter Official Media Partner

8 8 SIOG 2014 Accreditation The SIOG 2014 Annual Conference was granted 14 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). European Accreditation European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country. Accreditation Statement Accreditation by the EACCME confers the right to place the following statement in all communication materials including the registration website, the event programme and the certificate of attendance. The following statements must be used without revision: "The 'International Society of Geriatric Oncology' (or) 'SIOG 2014 Annual Meeting' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), "The 'SIOG 2014 Annual Meeting' is designated for a maximum of (or 'for up to') 14 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity." Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS- EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. EACCME credits Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event. The SIOG 2014 Conference is CME-certified by the European Society for Medical Oncology with 16, cat. 1 ESMO-MORA points. Programme under the auspices, endorsed or recommended by:

9 9 SIOG Programme at a Glance n Track 1: Solid Tumour in the Elderly n Track 2: Haem Malignancies in the Elderly n Track 3: New Therapies and Basic Science n Track 4: Nursing, Supportive Care and Geriatric Assessment n Track 5: Advocacy and Socio-economical Issues SIOG 2014 Thursday 23 October Friday 24 October Saturday 25 october Audi VII Audi VI Audi VII Audi VI Audi VII Audi VI Room 7 Conference Registration Opening Address Plenary Session 1 Advancement in the field of Geriatric Oncology 09:00-10:30 Coffee Break - Poster Walk Satellite Session Lunch Break - Poster Viewing Educational Publication Workshop Recent advances in the management of metastatic solid tumours Geriatric assessment in haematologic malignancies Plenary Session 2 Controversies in cancer screening in older patients Coffee Break - Poster Walk Special Partnership Session SIOG & EUGMS Interdisicplinary geriatric oncology models of care - the international perspective CLL in the elderly Lunch Break - Poster Viewing Plenary Session 3 State of the art and featured research session SIOG Presidential Session & Awards Coffee Break - Poster Walk Adjuvant therapy in older adults: controversies and challenges Satellite Session Understanding the needs of the caregiver: The lost patient Lunch Break - Poster Viewing SIOG General Assembly Audi VII EORTC elderly task force: example of a collaborative Satellite Session group for research in older cancer patients SIOG Membership & NR Committee Meeting (Closed Meeting) Young SIOG: General Assembly 12:45-13:15 Young SIOG: Peer to Peer Mentorship Session Satellite Session GU & lung cancer: geriatric assessment and clinical Social and cultural determinants of health in elderly cancer patients - SIOG & IPOS Session Sarcopenia, aging, and cancer in the light of basic science and therapeutic possibilities Optimizing communication & decision making Coffee Break - Poster Walk Coffee Break - Poster Walk Special SIOG Guidelines Session Young SIOG Investigator Award Geriatric syndromes in oncology Early breast cancer: from screening to adjuvant SIOG Nursing & Allied Health Award Poster Welcome Reception 18:30-19:30 SIOG 2014 Dinner Journal of Geriatric Oncology Publication Workshop The Art of Peer-Review Date: Thursday 23 October - Time: Participation is complementary and will include a boxed lunch. The Journal of Geriatric Oncology, the official journal of SIOG, will host a Publication Workshop during SIOG 2014 in Lisbon which will explore the art of peer-review. Editorin-Chief, Dr Arti Hurria (City of Hope, USA), and Deputy Editors, Dr Supriya Mohile (University of Rochester, USA) and Dr Siri Rostoft (University of Oslo, Norway), will explore the purpose of peer-review in scholarly medical publishing and look at the practical aspects of peer-review, including: n The role of the peer-reviewer n The process of peer-review n The approach to evaluating a manuscript and preparing a constructive peer-review report With time for discussion and questions, the Workshop will be valuable for early career researchers and clinicians who wish to become reviewers or who wish to understand the process of peer-review.

10 10 Thursday October 23, 2014 n Track 1 n Track 2 n Track 3 n Track 4 n Track 5 Letter "O" + Numbers: Oral Abstract Presentation 8:30-9:00 Opening Address - Auditorium VII Fernando Leal da Costa, Secretary of State Assistant to the Portuguese Minister of Health Arti Hurria (USA), Francisco Pimentel (PT) 09.00:10.30 Plenary session 1 Advancement in the field of geriatric oncology Arti Hurria (USA) & Muriel Rainfray (FR) 09:00-09:15 Update in medical oncology Vesa Kataja (FI) 09:15-09:30 Update in geriatrics Muriel Rainfray (FR) 09:30-09:45 Update in surgery Kwok Leung Cheung (GB) 09:45-10:00 Update in psycho oncology Jimmie Holland (USA) 10:00-10:15 Update in heamatology Reinhard Stauder (AT) 10:15-10:30 Questions & answers 10:30-11:00 Coffee Break - Poster Walk 1 11:00-12:30 Satellite Session (refer to page 14) - Auditorium VII 12:30-14:00 Lunch Break - Poster Viewing - Educational Publication Workshop (Auditorium VI) Parallel Session A1 - Auditorium VII 14:00-15:15 Recent advances in the management of metastatic solid tumours Hans Wildiers (BE); Supriya Mohile (USA) 14:00-14:15 Breast Laura Biganzoli (IT) 14:15-14:30 Renal Cell Supriya Mohile (USA) 14:30-14:45 Lung Ajeet Gajra (USA) 14:45-15:00 Melanoma Pascal Wolter (BE) 15:00-15:15 Questions & answers Parallel Session A2 - Auditorium VI 14:00-15:15 Geriatric assessment in haematologic malignancies Alfonso Cruz-Jentoft (ES); Vicki Morrison (USA) 14:00-14:15 O01 - Geriatric assessment before reduced intensity conditioning allogeneic hematologic stem cell transplantation in elderly patients Maud Cecile (FR) 14:15-14:30 O02 -The elderly project by the FIL (fondazione italiana linfomi): a project aimed at the prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma Francesco Merli (IT) 14:30-14:45 O03 -Impact of nutritional status on the clinical outcome of hematological malignancies in the elderly Julia Augschöll (AU) 14:45-15:00 O04 -Crash score in the older French non Hodgkin lymphoma patients receiving chemotherapy, first results Jean-Baptiste Fargeas (FR) 15:00-15:15 Discussant - Questions & answers Alfonso Cruz Jentoft (ES) 15:15-15:30 Technical Break 15:30-17:00 Satellite Session (refer to page 14) - Auditorium VII 17:00-17:30 Coffee Break - Poster Walk 2 Parallel Session B1 - Auditorium VII 17:30-18:30 Young Investigator Award Riccardo Audisio (GB); Arti Hurria (USA) Jury: Ajeet Gajra (USA); Franciso Pimentel (PT); Etienne Brain (FR); Vicki Morrison (USA); Andrea Maier (NL); Margot Gosney (GB); Beena Devi (MA); Riccardo Audisio (GB); Arti Hurria (USA) 17:30-17:45 O05 - Incidence of postoperative delirium in elderly cancer patient is correlated to the preoperative anticholinergic drug score Maren Schmidt (DE) 17:45-18:00 O06 - Surgical management of metastatic colon cancer: analysis of the surveillance, epidemiology and end results (SEER) database Ponnandai Somasundar (USA) 18:00-18:15 O07 - Evaluation of the role of sarcopenia in elderly patients with cancer treated with chemotherapy. Oncosarco project. Preliminary results MJ Molina Garrido (ES) 18:15-18:30 Questions & answers Parallel Session B2 - Auditorium VI 17:30-18:30 Geriatric syndromes in oncology Siri R. Kristjansson (NO); Margot Gosney (GB) 17:30-17:45 O08 - Modification of the G8 screening tool for frailty in elderly patients with cancer: the ELCAPA-07 cohort study Etienne Audureau (FR) 17:45-18:00 O09 - Multimorbidity and the aggressiveness of care near the end of life in older cancer patients Siran Koroukian (USA) 18:00-18:15 O10 - The prevalence of prostate cancer among elderly men with hip fractures and osteoporosis fragility fractures- a retrospective study of 2 databases to identify how to improve practice in older men with prostate cancer Sara Faithfull (GB) 18:15-18:30 Discussant - Questions & answers "Where to go next with the research - unanswered question" Siri R Kristjansson (NO) 18:30-19:30 Poster Welcome Reception

11 11 Friday October 24, 2014 Auditorium VII 08:30-10:00 Plenary Session 2 Controversies in cancer screening in older patients Vesa Kataja (FI); Etienne Brain (FR) 08:30-08:50 Colorectal Meri-Sisko Vuoristo (FI) 08:50-09:10 Lung Michael Jaklitsch (USA) 09:10-09:30 Breast Karsten Julh Jorgensen (DK) 09:30-09:50 Prostate William Dale (USA) 09:50-10:00 Questions & answers 10:00-10:30 Coffee Break - Poster Walk 3 10:30-11:30 Special Partnership Session (SIOG + EUGMS) Etienne Brain (FR); Alfonso Cruz Jentoft (ES) 10:30-10:45 Opening Address Alfonso Cruz Jentoft (ES) The role of the geriatrician in the multidisciplinary approach of treating older patient with cancer - the EUGMS perspective 10:45-10:55 Pre-operative assessment of older patient with cancer The point of view of the surgeon Barbara van Leeuwen (BE) 10:55-11:05 The point of view of the geriatrician Siri R. Kristjansson (NO) 11:05-11:15 Post-operative management of the older adults with cancer - The role of the surgeon Kwok Leung Cheung (GB) 11:15-11:25 The role of the geriatrician Sofia Duque (PT) 11:25-11:30 Questions & answers Parallel Session A1 - Auditorium VII 11:45-12:45 Interdisciplinary geriatric oncology models of care Siri R Kristjansson (NO); Aaron Begue (USA) the international perspective 11:45-12:00 USA models of care Aaron Begue (USA) 12:00-12:05 Discussion, questions & answers 12:05-12:20 European Models of Care Margot Gosney (GB) 12:20-12:25 Discussion, questions & answers 12:25-12:40 Latin American Models of Care Aldo Dettino (BR) 12:40:12:45 Questions & answers Parallel Session A2 - Auditorium VI 11:45-12:45 CLL in the elderly Vicki Morrison (USA); Reinhard Stauder (AT) 11:45-12:00 Assessing older patients with haematological malignancies Alfonso Cruz Jentoft (ES) 12:00-12:15 Incorporating newer treatment options - How will the new drugs modify the current standards? Michael Hallek (DE) 12:15-12:30 Supportive care in CLL Vicki Morrison (USA) 12:30-12:45 Questions & answers 12:45-14:00 Lunch Break - Poster Viewing Auditorium VII 13:00-13:45 SIOG General Assembly 14:00-15:30 Satellite Session (refer to page 15) - Auditorium VII Parallel Session B1 - Auditorium VII 15:45-17:00 GU & lung cancer: geriatric assessment and clinical Vesa Kataja (FI); William Dale (USA) 15:45-15:55 O11 - Chemotherapy feasibility in older patients with metastatic bladder cancer: the multicenter prospective cohort study agevim Marie Laurent (FR) 15:55-16:05 O12 - Toxicities and outcome in elderly patients treated with targeted therapies for metastatic renal cell carcinoma Olivier Rigal (FR) 16:05-16:25 Discussant: Question & answers Vesa Kataja (FI) 16:25-16:35 O13 - Impact of a comprehensive geriatric assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): a pooled analysis of two phase 2 prospective studies of the GFPC group Hervé Le Caer (FR) 16:35-16:45 O14 - Comparing comorbidity scales in patients with advanced non-small-cell lung cancer (NSCLC): clinician comorbidity score versus CIRS-G Lene Kirkhus (NG) 16:45-17:00 Discussant: Question & answers William Dale (USA) Parallel Session B2 - Auditorium VI 15:45-17:00 Social and cultural determinants of health in elderly cancer patients Lea Baider (IL); Lodovico Balducci (USA) SIOG & IPOS Session 15:45-16:00 Clinical geriatric case presentation Lea Baider (IL) 16:00-16:17 Coping styles in elderly patients Joachim Weis (DE) 16:17-16:34 Comorbidities and economical strain Lodovico Balducci (USA) 16:34-16:51 Meaning William Breitbart (USA) 16:51-17:00 Questions & answers Lea Baider (IL) 17:00-17:30 Coffee Break - Poster Walk 4

12 12 Friday October 24, 2014 Parallel Session C1 - Auditorium VII 17:30-18:30 Early breast cancer: from screening to adjuvant Hans Wildiers (BE) 17:30-17:42 O15 - Elderly patients with early breast cancer (BC) are less likely to receive adjuvant chemotherapy (adjct) irrespective of disease risk factors: the multidisciplinary application of genomics in clinical practice (magic) survey Christos Markopoulos (GR) 17:42-17:54 O16 - Unfavourable predictive factors in older women with clinically favourable breast cancer Mandy Kiderlen (NL) 17:54-18:06 O17 - Breast cancer screening in older women Nienke De Glas (NL) 18:06-18:30 Discussant: Question & answers Hans Wildiers (BE) Parallel Session C2 - Auditorium VI 17:30-18:30 SIOG Nursing & Allied Health Award Jury: Margot Gosney (GB); Edna Goncalves (PT); Aaron Begue (USA); Siri R Kristjansson (NO); Riccardo Audisio (GB) 17:30-17:45 O18 - A multidisciplinary educational course for oncology nurses to advance expertise in the care of older patients with cancer Heidi Yulico (USA) 17:45-18:00 O19 - Evaluation of a pharmacist-led medication assessment used to identify prevalence and associations with potentially inappropriate medication (pim) use among ambulatory senior adults with cancer Ginah Nightingale (USA) 18:00-18:15 O20 - Prognostic value of geriatric screening and assessment for overall survival in older patients with cancer Cindy Kenis (BE) 18:15-18:30 Questions & answers 19:00-22:30 SIOG 2014 Dinner Saturday October 25, 2014 Auditorium VII 08:00-09:00 Plenary Session 3 - Featured research session Arti Hurria (USA); Vesa Kataja (FN) 08:00-08:15 O21 - Effect of age on the efficacy and safety of Lenvatinib for the treatment of I 131-refractory differentiated thyroid cancer in the phase 3 SELECT study Marcia Brose (USA) 08:15-08:30 O22 - Evaluation of clinical and biological frailty markers in older breast cancer patients Bruna Dalmasso (BE) 08:30-08:45 O23 - Feasibility of tyrosine kinase inhibitor (TKI) treatment in older patients with PH+ chronic myeloid leukemia (CML). A Spanish group of CML (GELMC) retrospective study Concepcion Boque (ES) 08:45-09:00 Questions & answers 09:00-10:00 SIOG Presidential Session & Awards Arti Hurria (USA); Riccardo Audisio (GB) 09:00-09:20 Presentation1 (20mns) : Presidential address Etienne Brain (FR) 09:20-09:30 Presentation 2 (10mns): Calabresi award Martine Extermann (USA) 09:30-09:40 Presentation 3 (10mns): SIOG Nursing & Allied Health award Etienne Brain (FR); Arti Hurria (USA) 09:40-09:50 Presentation 4 (10mns): SIOG Young Investigator award Etienne Brain (FR); Arti Hurria (USA) 09:50-09:55 Presentation 5 (5mns): Best Poster award Etienne Brain (FR); Riccardo Audisio (GB) 09:55-10:00 Presentation 5 (5mns): SIOG 2015 annual conference announcement Etienne Brain (FR) 10:00-10:30 Coffee Break - Poster Walk 5 10:30-11:30 Satellite Session (please refer to page 15) - Auditorium VII Parallel Session A1 - Auditorium VI 11:45-12:45 Adjuvant therapy in older adults: controversies and challenges Etienne Brain (FR), Andrea Luciani (IT) 11:45-12:00 Breast Hans Wildiers (BE) 12:00-12:15 Lung Andrea Luciani (IT) :30 Colorectal Claus-Henning Köhne (DE) 12:30-12:45 Questions & answers Parallel Session A2 - Auditorium VI 11:45-12:45 Understanding the needs of the caregiver: The lost patient Beena Devi (MY); Muriel Rainfray (FR) 11:45-12:00 The functional and socio-economic impact of caregiving Tina Hsu (CA) 12:00-12:05 Questions & answers 12:05-12:20 The psychological impact of caregiving Jimmie Holland (USA) :25 Questions & answers 12:25-12:40 Assessing and supporting the caregiver: the nursing perspective Elisabete Valèrio (PT) 12:40-12:45 Questions & answers 12:45-14:30 Lunch Break - Poster Viewing

13 13 Saturday October 25, 2014 Auditorium VII 13:15-14:15 EORTC elderly task force: example of a collaborative group for research in older cancer patients Hans Wildiers (BE) Introduction Kostas Tryfonidis (GR) Achievements Hans Wildiers (BE) Current clinical trials Etienne Brain (FR) Geriatric assessment within EORTC Ulrich Wedding (DE) Future Hans Wildiers (BE) 13:15-14:15 SIOG Membership & NR Committee Meeting (closed meeting) - Auditorium VI Room 7 12:45-13:15 Young SIOG General Assembly 13:15-14:15 Young SIOG: Peer to Peer Mentorship session Andrea Maier (NL); Monique Slee-Valentijn (NL) Tips and tricks for research in geriatric oncology Martine Extermann (USA) Publishing in geriatric oncology: an editor s perspective Arti Hurria (USA) A clinical fellowship in geriatric oncology Ravindran Kanesvaran (SG) Summary and discussion Parallel Session B1 - Auditorium VII 14:30-15:30 Sarcopenia, aging and cancer in the light of basic science and therapeutic possibilities Andrea Maier (NL); Fatima Cardoso (PT) 14:30-14:45 The biology of sarcopenia with a focus on mitochonria Emanuele Marzetti (IT) 14:45-15:00 Cancer and preoperative sarcopenia interventions (clinical orientation) Carel Meskers (NL) 15:00-15:15 New interventions of sarcopeniea Christiaan Leeuwenburgh (USA) 15:15-15:30 Sarcopenia and cancer Andrea Maier (NL) Parallel Session B2 - Auditorium VI 14:30-15:30 Optimizing communication and decision making Elisabete Valerio (PT); Beena Devi (MY) 14:50-15:50 O26 - Patient-reported information on diagnosis and cancer treatments in older patients: a cross-sectional analysis of the ELCAPA cohort study Philippe Caillet (FR) 14:50-15:10 The geriatrician perspective TBC 15:10-15:30 The oncologist perspective Elisabete Valério (PT) 15:45-17:30 Special SIOG Guidelines Session - Auditorium VII Arti Hurria (USA); Etienne Brain (FR) 15:45-16:00 Oral Chemotherapy Laura Biganzoli (IT) 16:00-16:15 Radiotherapy Ian Kunkler (GB) 16:15-16:30 Colorectal Demetris Papamichael (CY) 16:30-16:45 DLBCL Vicki Morrison (USA) 16:45-17:00 Prostate Helen Boyle (FR) 17:00-17:15 Taxanes Laura Biganzoli (IT) 17:15-17:30 Nutrition Federicco Bozzetti (IT) 17:30 End of Conference

14 14 Industry Participation Satellite Sessions A number of Satellite Sessions are organised by the industry during the SIOG 2014 Conference. Prostate Cancer - Part 1: Optimizing Survival in Senior Adults with Advanced Prostate Cancer Thursday 23 October :00-12:30, Auditorium VII Chairman: Matti Aapro, Genolier, Switzerland 1. Management of prostate cancer in senior adults: a call to action Matti Aapro, Genolier, Switzerland 2. Understanding the heterogeneity of prostate cancer to guide treatment choices Nicolas Mottet, Saint-Etienne, France 3. Tailoring therapy in advanced prostate cancer Stéphane Oudard, Paris, France 4. SIOG guidelines for the management of senior adults with advanced prostate cancer Jean-Pierre Droz, Lyon, France The Ageing Process: Does it Matter when Considering Lymphoproliferative Disorders and Supportive Care? Thursday, 23 October 2014, 15:30-17:00, Auditorium VII 15:30-15:35 Welcome and introduction Matti Aapro, Genolier, Switzerland 15:35-16:00 Adapting lymphoproliferative treatment in older adults Ruth Pettengell, St George's University of London, London, GB 16:00-16:20 Chemotherapy-induced neutropenia and the role of G-CSF in older patients Antonio Pinto, National Cancer Institute Foundation G. Pascale, Naples, Italy 16:20-16:45 Past, present and future of erythropoietin use in anaemia in older adults Reinhard Stauder, Innsbruck, Medical University, Innsbruck, Austria 16:45-16:55 Panel Q&A session All faculty 16:55-17:00 Closing remarks Matti Aapro, Genolier, Switzerland

15 15 Industry Participation Prostate Cancer - Part 2: Management of Older Patients with Prostate Cancer: Translating Data into Daily Clinical Practice Friday 24 October :30, Auditorium VII Chair: Lodovico Balducci, USA Faculty: N Mottet, France, H Payne, GB E Efstathiou (Greece), N Clarke (GB), (via videolink) Introduction Lodovico Balducci, USA Challenges in the management of older patients with metastatic CRPC Noel Clarke (via videolink) Updated SIOG recommendations for the management of older patients with prostate cancer Assessment, health status screening and treatment of localized disease Nicolas Mottet, France Recommendations for management of advanced disease including metastatic CRPC Heather Payne, GB Considerations for Immuno-Oncology in Elderly Patients: A New Age in Therapy for Multiple Tumor Types Saturday 25 October - 10:30-11:30, Auditorium VII Chair: Enriqueta Felip, Spain 10:30-10:45 Welcome and Introduction: Immuno-oncology as an approach in multiple tumor types Enriqueta Felip, Spain 10:45-11:05 PD1 inhibitors in advanced NSCLC Case study: Platinum-treated, progressive metastatic NSCLC Enriqueta Felip, Spain :25 PD1 inhibitors in advanced melanoma Ana Raimundo, Portugal 11:25-11:30 Q&A and close Ana Raimundo, Portugal

16 16 Scientific Display at SIOG 2014 An open space in the poster area has been provided for industry partners to set-up a scientific display showcase. Coffee breaks will all take place in the open space promoting frequent and repeated opportunities for the delegates to visit the posters and displays. Exhibition Opening Hours n Thursday 23 October :30 n Friday 24 October :30-18:00 n Saturday 25 October :30-15:00 Scientific Display and Poster Plans Stands SIOG Stand 1 Genomic Health Stand 2 Elsevier/JGO Stand 3

17 17 Sponsors and Exhibitors Profile (Profiles provided by the sponsors & exhibitors) Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information Celgene International SARL Route de Perreux Boudry - Switzerland - Celgene is a global biopharmaceutical company involved in the discovery, development and commercialization of products for the treatment of cancer, inflammatory and immunological diseases. At Celgene, we seek to deliver truly innovative and life-changing treatments for our patients. Genomic Health - Stand n 2 Quai du Seujet Geneva, Switzerland - Genomic Health, Inc. is a world's leading provider of genomic-based diagnostic tests that inform treatment decisions and help to ensure each patient receives appropriate treatment for early stage cancer. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit Gilead Sciences Europe LTD. 2 Roundwood Avenue, Stockley Park Exbridge, UB 11 1AF - United Kingdom - At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life - threatening diseases around the world. GSK 1250 South Collegeville Road - Collegeville, PA USA - GSK Oncology is dedicated to the patients, physicians and communities pursuing the fight against cancer. At GSK Oncology, what defines us is our pledge to engage and work in concert with our communities. At GSK Oncology, our portfolio of medicines represents a heritage spanning more than five decades. Whether you are a physician, researcher, or patient, we aspire to know how GSK Oncology might engage with you in fighting the global pandemic known as cancer. HOSPIRA Hospira is the world s leading provider of injectable generic drugs and infusion technologies. Through its broad integrated portfolio Hospira is uniquely positioned to improve patient and caregiver safely whilst reducing healthcare costs. Hospira offers a broad range of generic acute-care and oncology injectables, biosimilar medicines and integrated infusion therapy and medication management solutions. Learn more about Hospira at Helsinn Healthcare S.A. Via Pian Scairolo, Lugano-Pazzallo - Switzerland - Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 and headquartered in Lugano, Switzerland, Helsinn has subsidiaries in Switzerland, Ireland, US, and a Representative Office in China. Helsinn s business model is focused on developing, registering and licensing pharmaceuticals, medical devices and nutritional supplement products in the cancer care area through partner companies, and marketing pharmaceutical products in the US through its subsidiary Helsinn Therapeutics (U.S.), Inc. Janssen Pharmaceuticals Turnhoutseweg 30 - B-2340 Beerse - Belgium - The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, Janssen develops innovative products, services and healthcare solutions to help people throughout the world. More information can be found at

18 18 Elsevier / Journal of Geriatric Oncology - Stand n 3 The Boulevard, Langford Lane, Kidlington - Oxford, OX5 1GB - United Kingdom - The Journal of Geriatric Oncology - published by Elsevier - the official journal of the International Society of Geriatric Oncology - is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. Edited by Dr Arti Hurria, City of Hope, USA, the journal publishes original research articles, review articles, clinical trials, short communications and correspondence. MSD One Merck Drive WS2C36A - Whitehouse Station, NJ USA - Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit or Pierre Fabre 45 place Abel Gance Boulogne Cedex - France - Pierre Fabre is present in more than 140 countries worldwide. Our oncology products are Navelbine Oral (oral vinorelbine) for the treatment of advanced breast cancer and non-small cell lung cancer, and Javlor (vinflunine) for the treatment of advanced urothelial carcinoma after failure of a platinum containing regimen. Javlor is currently under phase III development for the advanced breast cancer. Sanofi 54 Rue de la Boetie Paris - France - Sanofi Oncology, a global division of Sanofi, is dedicated to the discovery, development and delivery of effective therapeutics that address unmet medical need for cancer patients. We are building a renewed and diversified oncology portfolio, driven by the principles of innovation, personalization and patient access to medicines. Through partnerships and collaborations with leading experts in the areas of research, clinical practice, patient experience and patient access, Sanofi Oncology aims to deliver innovative treatment solutions that provide meaningful benefit to patients around the world. We are currently marketing 10 products to address select solid tumors, hematological conditions and organ transplantation. SIOG - Stand n 1 International Society of Geriatric Oncology Route des Morillons - P.O. Box Geneva - Switzerland - The International Society of Geriatric Oncology is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals and has over 1500 members in more than 40 countries around the world. The major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is before us.the mission of SIOG is to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment and care of older adults with cancer. Learn more about SIOG at TEVA Piet Heinkade GM Amsterdam - The Netherlands - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules.

19 19 List of Poster Presentations (Abstract titles as submitted by the authors - Only presenting authors are listed below. For the complete list of authors, please refer to the conference on-line abstract book). Poster Walk 1: Thursday 23 October 10:30-11:00 Chairs Track 1: Ajeet Gajra (USA); Riccardo Audisio (GB) Chairs Track 4: Aaron Begue (USA); Siri Rostoft Kristjansson (NO) Poster Walk 2 : Thursday 23 October 17:00-17:30 Chairs Track 1: Hans Wildiers (BE); William Dale (USA) Chairs Track 4: Margot Gosney (GB); Edna Gonçalves (PT) Poster Walk 3: Friday 24 October 10:00-10:30 Chairs Track 1: Ajeet Gajra (USA); Hans Wildiers (BE) Chairs Track 4: Aaron Begue (USA); Margot Gosney (GB); Chairs Track 5: Muriel Rainfray (FR); Elisabete Valério (PT) Poster Walk 4: Friday 24 October 17:00-17:30 Chairs Track 1: Ajeet Gajra (USA); William Dale (USA) Chairs Track 2: Alfonso Cruz-Jentoft (ES); Maria Gomes da Silva (PT); Chairs Track 2: Vicky Morrison (USA) Chairs Track 4: Siri Rostoft Kristjansson (NO); Edna Gonçalves (P) Poster Walk 5: Saturday 25 October 10:00-10:30 Chairs Track 1: William Dale (USA); Francisco Pimentel (PT) Chairs Track 3: Andrea Maier (NL); Berta Sousa (PT) Chairs Track 4: Margot Gosney (GB); Siri Rostoft Kristjansson (NO) Poster Walk 1 Poster Walk 2 Poster Walk 3 NO. / ABST. PRESENTER ABSTRACT TITLE TRACK 1: SOLID TUMOURS IN ELDERLY 1.1 BREAST CANCER IN ELDERLY PATIENTS P001 Y. Phan BREAST CANCER IN THE ELDERLY P002 B. Gonçalves TRASTUZUMAB-INDUCED CARDIOTOXICITY AMONG ELDERLY BREAST CANCER PATIENTS P004 M. Kiderlen MANAGEMENT OF EARLY STAGE BREAST CANCER IN OLDER PATIENTS - AN INTERNATIONAL COMPARISON OF STANDARD CARE VERSUS ONCOGERIATRIC CARE P005 P006 P007 P009 P. Ciammella N. de Glas V. Hamelinck E. Brain OUTCOMES AND TOXICITIES IN ELDERLY FEMALES TREATED FOR BREAST CANCER WITH HYPOFRACTIONATED RADIATION THERAPY. METHODS IN CONDUCTING OBSERVATIONAL RESEARCH RELATED TO TREATMENT OF OLDER BREAST CANCER PATIENTS - A SYSTEMATIC REVIEW A COMPARISON OF YOUNGER AND OLDER PATIENTS PREFERENCES FOR ADJUVANT CHEMOTHERAPY AND HORMONAL THERAPY IN EARLY BREAST CANCER ASTER 70S UNICANCER PHASE III TRIAL: CAN A GENOMIC PROGNOSTICATOR HELP TAILORING ADJUVANT SYSTEMIC TREATMENT FOR LUMINAL BREAST CARCINOMA IN ELDERLY WOMEN? P010 K-L. Cheung LKB1 - A POTENTIAL NOVEL BIOMARKER AND CLINICAL SIGNIFICANCE IN BREAST CANCER P011 R. Parks COMPARISON OF QUALITY OF LIFE (QOL) SCORE FOLLOWING INITIAL TREATMENT OF SURGERY OR NON-SUR- GERY IN OLDER WOMEN WITH PRIMARY OPERABLE BREAST CANCER P012 M. Cruz-Ramos GERIATRIC ASSESSMENT IN LATIN BREAST CANCER PATIENT P013 A. P. Nogueira BREAST CANCER IN A GERIATRIC POPULATION WHAT DO WE NEED TO CHANGE? P014 O. Rigal FEASIBILITY OF ADJUVANT CHEMOTHERAPY IN BREAST CANCER WOMEN OVER 70 YEARS AFTER COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) P015 A. Jagiello-Gruszfeld RETROSPECTIVE STUDY COMPARING TOLERABILITY OF TRASTUZUMAB AS ADJUVANT SETTING IN TWO GROUP OF EARLY BREAST CANCER PATIENTS: 70 YEARS VS < 70 YEARS. P016 M. Extermann PHYSICAL PERFORMANCE AND BIOLOGICAL CORRELATES OF FUNCTIONAL LIMITATION IN OLDER BREAST CANCER SURVIVORS 1-2 YEARS FOLLOWING SURGICAL TREATMENT WITH AND WITHOUT CHEMOTHERAPY P017 C. Pinto HER2 POSITIVE IN ELDERLY POPULATION - A SINGLE CENTER EXPERIENCE P018 J. Rato A SINGLE CENTER FIVE YEAR FOLLOW UP ANALYSIS OF ELDERLY PATIENTS WITH BREAST CANCER 1.2 Prostate, bladder, kidney cancer in elderly patients AN ATTENUATED DOSE OF SUNITINIB SHOWS EQUAL EFFICACY AND WITH HIGHER DOSE DISCONTINUATIONS IN P019 R. Kanesvaran ELDERLY PATIENTS COMPARED WITH YOUNGER PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

20 20 Poster Walk 1 Poster Walk 5 Poster Walk 4 Poster Walk 5 Poster Walk 4 Poster Walk LUNG CANCER IN ELDERLY PATIENTS P020 M. Knetki-Wroblewska EGFR TYROSINE KINASE INHIBITORS IN FIRST-LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON- SMALL-CELL LUNG CANCER P022 M. Jaklitsch INCREASING AGE AND FAMILY HISTORY DISPROPORTIONATELY INCREASE RISK OF LUNG CANCER P024 G. S. Bhattacharyya PROGNOSTIC VALUE OF C-REACTIVE PROTEIN AND LACTIC DEHYDROGENASE AND HEMOGLOBIN IN ADVANCED NON SMALL CELL LUNG CANCER P025 G. S. Bhattacharyya PILOT PHASE II STUDY OF AN EXERCISE INTERVENTION FOR ADVANCED LUNG CANCER PATIENTS STAGE IIIB AND C POST CONCOMITANT CT/RT BY A HOME BASED PROTOCOL P026 R. Corre MULTICENTRIC, RETROSPECTIVE STUDY EVALUATING THE EPIDEMIOLOGIC CHARACTERISTICS AND OUTCOMES OF PATIENTS AGED 80 YEARS OR OLDER WITH NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATIONS TREATED BY EGFR-TKI P027 A. Karampeazis GEMCITABINE COMBINED WITH CARBOPLATIN IN THE FIRST-LINE TREATMENT OF ELDELRY PATIENTS WITH NON-SMALL- CELL LUNG CANCER: A MULTICENTER PHASE II TRIAL BY THE HELLENIC ONCOLOGY RESEARCH GROUP (HORG) P028 A. Pluzanski PLATINUM-BASED CHEMOTHERAPY VERSUS MONOTHERAPY IN FIRST-LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER Colorectal cancer in elderly patients P029 T. Rama 80 YEARS AND BEYOND: SAFETY AND LEGITIMACY OF COLORECTAL CANCER SURGERY P030 F. Van Erning DRUG USE AMONG ELDERLY SHORTLY BEFORE COLON CANCER DIAGNOSIS P031 A. Costanzi GENITO-URINARY DISORDERS AFTER UNCOMPLICATED LAPAROSCOPIC RECTAL RESECTION FOR CANCER IN A SERIES OF 30 NON-IRRADIATED ELDERLY PATIENTS. P032 A. Jagiello-Gruszfeld CETUXIMAB AND PANITUMUMAB IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER. 1.7 Targeted therapies in elderly cancer patients P033 M. Appleby DIFFERENCES IN THE INVESTIGATION AND TREATMENT OF ELDERLY PATIENTS WITH CANCER WHEN COGNITIVE IMPAIRMENT IS PRESENT. P034 M. Burgy CETUXIMAB PLUS PLATINUM-BASED CHEMOTHERAPY IN ELDERLY PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA: A FRENCH EXPERIENCE FROM A SINGLE INSTITUTION 1.8 Clinical trials for elderly cancer patients P035 H. Le Caer ELDERLY HEAD AND NECK CANCER (ELAN) STUDY: PERSONALIZED TREATMENT ACCORDING TO GERIATRIC ASSESSMENT IN PATIENTS AGE 70 OR OLDER : FIRST(SCCHN) UNSUITABLE FOR SURGERY P036 J. Eriksen NO IMPACT OF AGE, COMORBIDITY AND WHO PERFORMANCE ON DELAY OF TREATMENT IN PATIENTS UNDERGOING FAST-TRACK WORK-UP FOR HEAD AND NECK CANCER (H&N) Track 2: Haem Malignancies in the Elderly 2.1 Haematological cancer in elderly patients P038 N. Signol DISRUPTION OF THE CLINICAL CARE PATHWAY IN GERIATRIC HEMATOLOGY: IMPACT OF THE GERIATRIC ASSESSMENT P039 P. Ciammella A MULTICENTRIC RETROSPECTIVE ANALYSIS ON CLINICAL OUTCOMES FOR ELDERLY PATIENTS WITH STAGE I-II DIFFUSE LARGE B-CELL LYMPHOMA. 2.4 Myeloma in the elderly P040 B. Beauplet POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS TREATED FOR MULTIPLE MYELOMA Track 3: New Therapies and Basic Science 3.1 Basic research P041 A. Aaldriks THREE COMPONENTS OF A GERIATRIC SCREENING DETERMINE THE GERIATRIC PROGNOSTIC INDEX (GPI) AS RISK PROFILE BEFORE CHEMOTHERAPY IN THE ELDERLY 3.4 Epidemiology P043 E. Bastiaannet INTERNATIONAL COMPARISONS USING COUNTRY AS INSTRUMENTAL VARIABLE IN GERIATRIC ONCOLOGY P044 A. Oliveira THE NEW OLD BREAST CANCER POPULATION IN FARO HOSPITAL-ALGARVE REGION Targeted therapies in elderly cancer patients P045 L. Loftus INTRAOPERATIVE RADIOTHERAPY FOR EARLY BREAST CANCER AND AGE: CLINICAL CHARACTERISTICS AND OUTCOMES P046 P. Ghia SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA Track 4: Nursing, Supportive Care and Geriatric Assessment 4.1 Geriatric Assessment P048 K. Alexander POST SURGICAL SKILLED CARE UTILIZATION AT HOSPITAL DISCHARGE IN OLDER CANCER PATIENTS P049 A. MacKenzie ADHERENCE TO GUIDELINES IN SENIOR ADULT ONCOLOGY PATIENTS: IS STANDARD CARE THE RIGHT CARE? P051 M. Puts A FEASIBILITY TRIAL OF GERIATRIC ASSESSMENT AND MANAGEMENT FOR OLDER CANCER PATIENTS

21 21 P052 A. Naeim ACCURATE CLASSIFICATION OF PERFORMANCE STATUS IN ELDERLY PATIENTS: DESIGN, VALIDATION AND IMPLEMENTATION OF A REMOTE PATIENT ACTIVITY MONITORING DEVICE P053 R. Vreeswijk DEVELOPMENT AND VALIDATION OF THE DELIRIUM RISK ASSESSMENT SCORE (DRAS) Poster Walk 2 P054 S. Chow INITIAL EXPERIENCE OF A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS 60 YEARS AND OLDER P055 A. O'Donovan MANAGING THE ELDERLY IN RADIOTHERAPY USING GERIATRIC ASSESSMENT (MERGE): A PILOT STUDY P056 M. Molina-Garrido METHODS TO DETECT AND TO EVALUATE FRAILTY (ONCOFRAGIL PROJECT) P057 A. Junqueira dos Santos SPONTANEOUS DAILY PHYSICAL ACTIVITY AND ITS ASSOCIATION WITH FUNCTIONAL CAPACITY, BODY COMPOSITION AND MUSCLE QUALITY IN OLDER PATIENTS WITH CANCER CACHEXIA SYNDROME. P056 M.Huisman Impaired cognitive function, depression and fatigue: risk factors of 30-day mortality in oncogeriatric surgical patients. The preop-study P058 H. Holmes THE USE OF GERIATRIC ASSESSMENT TO PREDICT FRAILTY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION P059 J. Moon PREVALENCE OF SARCOPENIA AND ITS ASSOCIATION WITH METABOLIC SYNDROME IN KOREAN CANCER SURVIVORS P060 S. Valero A COMPARISON OF TWO SCREENING TOOLS IN ELDERLY PATIENTS WITH MALIGNANCIES. P061 L. Keenan ASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN OLDER PATIENTS UNDERGOING RADIOTHERAPY P062 B. Korc-Grodzicki BUILDING A GERIATRICS SERVICE IN A CANCER CENTER: LESSONS LEARNED DURING ITS FIRST 5 YEARS P063 S-R. Choo THE ASSOCIATION BETWEEN CANCER AND FALLS IN THE ELDERLY AND THE RELATIONSHIP BETWEEN FALLS AND SARCOPENIA IN ELDERLY INDIVIDUALS WITH CANCER Poster Walk 2 P064 C. Kenis IMPLEMENTATION OF GERIATRIC ASSESSMENT IN BELGIAN PATIENTS WITH CANCER: A MULTICENTER SURVEY ON TREATING PHYSICIANS GENERAL EXPERIENCES AND EXPECTATIONS P065 C. Kenis IMPLEMENTATION OF GERIATRIC ASSESSMENT IN OLDER PATIENTS WITH CANCER: FACILITATORS AND BARRIERS P066 E. Crétel Durand GERIATRIC PROFILE OF ELDERLY PATIENTS TREATED FOR PANCREATIC CANCER. P067 C. Handforth POLYPHARMACY IN OLDER CANCER PATIENTS: MEDICATION FOR SECONDARY PREVENTION P068 H. Yin VALIDATION OF G-8 SCREENING TOOL FOR COMPREHENSIVE GERIATRIC ASSESSMENT & POST-OPERATIVE DELIRIUM IN GYNECOLOGICAL CANCER PATIENTS UNDERGOING ROBOTIC SURGERY P069 M. Slee-Valentijn THE IMPACT OF COMPREHENSIVE GERIATRIC ASSESSMENT ON FINAL TREATMENT DECISIONS P069 S. Trarieux-Signol Qualitative research on the unwillingness of elderly patients' to participate in clinical research. P070 P074 P075 P077 P078 M. Roos E. Castel-Kremer F. Cornelis N. Ommundsen J. Augschöll IMPROVING CANCER CARE IN ELDERLY PATIENTS BY USING A COMMUNICATION BOOKLET: A PROSPECTIVE MULTICENTER BELGIAN STUDY PANCREATIC ADENOCARCINOMA IN ELDERLY PATIENTS :BENEFITS ON ONCOGERIATRIC APPROACH AND ONCOLOGICAL CARE GERIATRIC INTERVENTIONS IN OLDER CANCER PATIENTS: INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY (SIOG) RECOMMENDATIONS. INDIVIDUAL COMPONENTS OF GERIATRIC ASSESSMENT FOR PREDICTION OF FIVE YEAR SURVIVAL AFTER SURGERY FOR COLORECTAL CANCER RELEVANCE OF PPT AND VES-13 FOR MULTIDIMENSIONAL GERIATRIC ASSESSMENT AND FOR PREDICTION OF SURVIVAL IN ELDERLY CANCER PATIENTS Poster Walk 3 P079 A. Magnuson HIGHER SYMPTOM BURDEN IS ASSOCIATED WITH FUNCTIONAL IMPAIRMENT AND FALLS IN OLDER ADULTS WITH CANCER. P080 M. Extermann RATE OF CHANGE WITH AGE OF GERIATRIC INSTRUMENT SCORES IN CANCER PATIENTS P082 P083 R. Boulahssass R. Boulahssass POOR NUTRITIONAL STATUS IS AN INDEPENDENT FACTOR OF WORSE OUTCOMES IN THE SECOND GROUP OF BALDUCCI SCORE. TREATMENT DECISIONS FOR OLDER PATIENTS WITH CANCER. INFLUENCE OF THE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) AND THE CHOICE OF THE PATIENT AND THEIR CAREGIVER. P086 F. Ghignone STATE OF THE ART IN THE ASSESSMENT AND MANAGEMENT OF ONCOGERIATRIC SURGICAL PATIENTS. RESULTS FROM THE SIOG SURGICAL TASK FORCE SURVEY AMONG ESSO AND SSO MEMBERS P087 A. Gajra ASSESSING THE VALIDITY OF THE CARG (CANCER AND AGING RESEARCH GROUP) CHEMOTHERAPY TOXICITY SCORE FOR REDUCED MODELS 4.2 Nursing P088 B. Beauplet SKIN CANCER SCREENING BY NURSES IN ELDERLY DURING HOSPITALIZATION IN ACUTE GERIATRIC UNIT P089 P. Burhenn IMPLEMENTING AN EDUCATIONAL INITIATIVE TO PROMOTE SLEEP

22 22 Poster Walk 4 Poster Walk 5 Poster Walk 3 P090 P. Burhenn DEVELOPING A GERIATRIC RESOURCE INTERDISCIPLINARY TEAM IN GERIATRIC ONCOLOGY P091 P. Stolz Baskett MET AND UNMET NEEDS OF INFORMAL CAREGIVERS OF OLDER CANCER PATIENTS HAVING CHEMOTHERAPY P092 C. Abarado IMPROVING CONSTIPATION MANAGEMENT IN ONCOLOGY: A UNIT-LEVEL IMPLEMENTATION OF CONSTIPATION RISK ASSESSMENT SCALE ( ) 4.3 Nutrition P094 S. Luce PREVALENCE OF MALNUTRITION, SARCOPENIA AND CACHEXIA IN OLDER CANCER PEOPLE 4.4 Supportive care in elderly cancer patients P095 B-L. Nguyen HEALTH CARE EXPERIENCE OF ELDERLY CANCER PATIENTS VISITING THE EMERGENCY DEPARTMENT P096 V. Antoine PROFESSIONAL S EXPECTATIONS TO IMPROVE QUALITY OF CARE, SUPPORTIVE HEALTH CARE AND SOCIAL SERVICES UTILIZATION IN GERIATRIC ONCOLOGY P097 M. Puts A SYSTEMATIC REVIEW OF FACTORS INFLUENCING OLDER ADULTS' DECISION TO ACCEPT OR DECLINE CANCER TREATMENT IN STUDIES EXAMINING ACTUAL TREATMENT DECISIONS P098 M. Puts THE DEVELOPMENT OF A QUESTIONNAIRE TO MEASURE REASONS WHY OLDER ADULTS ACCEPT OR DECLINE CANCER TREATMENT P099 N. Sharma IMPACT OF AGE ON UTILIZATION OF ACUTE CARE SERVICES (ACS) AND PALLIATIVE CARE (PC) IN VETERANS WITH ADVANCED LUNG CANCER (ALC) P100 M. Frederic BIOSIMILAR FILGRASTIM IN THE TREATMENT AND THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA: THE NEXT STUDY P101 M. Frederic BIOSIMILAR FILGRASTIM IN THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN ELDERLY PATIENTS: A SUBANALYSIS OF THE NEXT STUDY P102 M. Aapro SAFETY AND EFFICACY OF NEPA, A FIXED ORAL DOSE COMBINATION OF NETUPITANT AND PALONOSETRON, IN OLDER PATIENTS P103 C. Robb IMPACT OF TIME, PERSONAL CONTROL AND SELF-RATED HEALTH ON OLDER CANCER PATIENTS UNDERGOING A CHEMOTHERAPY REGIMEN P104 G. Fasce QUALITIY OF LIFE OF ELDERLY CANCER PATIENTS IN CHILE P107 K. Cheng QUALITY OF LIFE OF ELDERLY PATIENTS RECEIVING CANCER THERAPY: A SYSTEMATIC REVIEW P108 T. Landre PAIN REPORTS AND PAIN MEDICATION TREATMENT IN ELDERLY PATIENTS WITH CANCER: A RETROSPECTIVE COHORT STUDY OF 311 PATIENTS P109 D. Tremblay PERCEIVED SELF-MANAGEMENT FOR OLDER ADULTS WITH CANCER: DOES MULTI-DISCIPLINARY TEAMWORK MAKE A DIFFERENCE? P110 R. Boulahssass MONITORING OF ELDERLY CANCER PATIENTS P111 W. Gianni ORAL SR OXYCODONE/NALOXONE (OXYNAL) IS EFFECTIVE IN ELDERLY CANCER PATIENTS WITH GOOD TOLERANCE IN NCS SYSTEM 4.5 Families P112 J. Marcotte FAMILY CAREGIVERS OF ELDERLY PATIENT WITH CANCER: A PROTOCOL ON NEEDS AND PERCEIVED PROMIZING INTERVENTIONS Track 5: Advocacy and Socio-Economical Issues 5.1 Advocacy & policies P113 F. Calacsan ATTITUDES OF PATIENTS TOWARDS CANCER CLINICAL TRIALS 5.2 Communication P114 S. Luce A MOBILE ONCOGERIATRIC TEAM (MOT) IN A BELGIAN ACADEMIC HOSPITAL: WHAT IS THE OPINION OF ELDERLY CANCER PATIENTS? P115 P. Somasundur UNDERSTANDING THE IMPORTANCE OF CAREGIVERS IN IMPROVING THE CARE OF GERIATRIC ONCOLOGY PATIENTS 5.3 Demography and longevity P117 J-M. Brechot AGING AND CANCER CARE IN FRANCE: DISTRIBUTION OF HOSPITAL ACTIVITY IN 2012 P118 C. Robb IMPACT OF URBAN/RURAL RESIDENCY AND POVERTY LEVEL ON SURVIVORSHIP IN OLDER ADULTS DIAGNOSED WITH LUNG CANCER IN GEORGIA, USA P114 H. Wildiers Geriatric assessment in older cancer patients: international society of geriatric oncology (siog) recommendations 5.6 Networks P119 B. Beauplet CONTINUING PROFESSIONAL TRAINING PROGRAM IN SKIN CANCER SCREENING IN ELDERLY Please note that the following posters have been withdrawn: PO3, PO08, PO23, PO37, PO42, PO50, PO71, PO72, PO73, PO76, PO81, PO84, PO85, PO93, P105, P106, P116.

23 23 List of Speakers & Chairpersons Aapro, Matti (CH) Audisio, Riccardo (GB) Baider, Lea (IL) Balducci, Lodovico (USA) Begue, Aaron (USA) Biganzoli, Laura (IT) Boyle, Helen (FR) Bozzetti, Federicco (IT) Brain, Etienne (FR) Breitbart, William (USA) Cardoso, Fatima (PT) Cheung, Kwok-Leung (GB) Cruz-Jentoft, Alfonso (ES) Dale, William (USA) Dettino, Aldo (BR) Devi, Beena (MY) Droz, Jean-Pierre (FR) Duque, Sofia (PT) Extermann, Martine (USA) Falandry, Claire (FR) Felip, Enriqueta (ES) Gajra, Ajeet (USA) Gonçalves, Edna (PT) Gosney, Margot (GB) Hallek, Michael (DE) Holland, Jimmie C. (USA) Hsu, Tina (CA) Hurria, Arti (USA) Jaklitsch, Michael (USA) Juhl Jørgensen, Karsten (DK) Kanesvaran, Ravindran (SG) Kataja, Vesa (FI) Köhne, Claus-Henning (DE) Kunkler, Ian (GB) Kristjansson, Siri. R (NO) Leeuwenburgh, Christiaan (USA) Luciani, Andrea (IT) Maier, Andrea (NL) Marzetti, Emanuele (IT) Meskers, Carel (NL) Mohile, Supriya (USA) Morrison, Vicki (USA) Mottet, Nicolas (FR) Oudard, Stéphane (FR) Pais, Ana (PT) Papamichael, Demetris (CY) Payne, Heather (GB) Pettengell, Ruth (UK) Pinto, Antonio (IT) Pimentel, Francisco (PT) Rainfray, Muriel (FR) Raimundo, Ana (PT) Slee-Valentjin, Monique (NL) Stauder, Reinhard (AT) Tryfonidis, Kostas (GR) Valério, Elisabete (PT) van Leeuwen, Barbara (NL) Vuoristo, Meri-Sisko (FI) Wedding, Ulrich (DE) Weis, Joachim (DE) Wildiers, Hans (BE) Wolter, Pascal (BE)

24 24 Speaker Disclosures Matti Aapro Riccardo Audisio Lea Baider Lodovico Balducci Aaron Begue Laura Biganzoli Helen Boyle Federicco Bozzetti Etienne Brain William Breitbart Fatima Cardoso Kwok-Leung Cheung Alfonso Cruz-Jentoft William Dale Aldo Dettino Beena Devi Jean-Pierre Droz Sofia Duque Martine Extermann Claire Falandry Enriqueta Felip Ajeet Gajra Edna Gonçalves Margot Gosney Michael Hallek Jimmie C. Holland Tina Hsu Arti Hurria Michael Jaklitsch Karsten Juhl Jørgensen Ian Kunkler Ravindran Kanesvaran Vesa Kataja Claus-Henning Köhne Siri. R Kristjansson Christiaan Leeuwenburgh Andrea Luciani Andrea Maier Emanuele Marzetti Carel Meskers Supriya Mohile Vicki Morrison Nicolas Mottet Stéphane Oudard Ana Pais Demetris Papamichael Heather Payne Francisco Pimentel Ruth Pettengell Antonio Pinto Muriel Rainfray Ana Raimundo Monique Slee-Valentjin Reinhard Stauder Kostas Tryfonidis Elisabete Valério Barbara van Leeuwen Meri-Sisko Vuoristo Ulrich Wedding Joachim Weis Hans Wildiers Pascal Wolter Is/has been a consultant for: Amgen, Astellas, BMS, Celgene, GSK, Helsinn, Hospira, Novartis, Merck, Merck Serono, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Teva, Vifor. Has received honoraria for lectrues at symposia of: Is/has been a consultant for: Amgen, Astellas, BMS, Celgene, GSK, Helsinn, Hospira, Novartis, Merck, Merck Serono, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Teva, Vifor Honoraria (presentations): jansen, Sanofi, Pfizer, Pierre Fabre, Novartis I have received funds for research on oncological geriatric assessment from Celgene Advisory / Consultant role: Helsinn Therapeutics, Merck, and Grant/research support from: Celgene For work performed outside the scope of the presentationv - Research funding: Celgene, Glaxosmithkline / Consultant fees: Seattle Genetics, GTX Inc

25

26 SIOG Guidelines now available! Prostate Cancer in Senior Adults Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T. Lancet Oncol Aug;15(9):e404-e414. doi: /S (14)70018-X. Comprehensive Geriatric Assessment International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, Flamaing J, Karnakis T, Kenis C, Audisio RA, Mohile S, Repetto L, Van Leeuwen B, Milisen K, Hurria A. The J Clin Oncol Jul 28. pii: JCO Colorectal Cancer in the Elderly Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations D. Papamichael, R. A. Audisio, B. Glimelius, A. de Gramont, R. Glynne-Jones, D. Haller, C.-H. Köhne, S. Rostoft, V. Lemmens, E. Mitry, H. Rutten, D. Sargent, J. Sastre, M. Seymour, N. Starling, E. Van Cutsem & M. Aapro. Ann Oncol Jul 11. pii: mdu253. Screening tools in older cancer patients Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. L. Decoster, K. Van Puyvelde, S. Mohile, U. Wedding, U. Basso, G. Colloca, S. Rostoft, J. Overcash, H. Wildiers, C. Steer, G. Kimmick, R. Kanesvaran, A. Luciani, C. Terret, A. Hurria, C. Kenis, R. Audisio & M. Extermann. Ann Oncol Jun 16. pii: mdu210. Lung Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, Luciani A, O'Brien M. Ann Oncol Mar 16. Radiotherapy Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange JL, Markouizou A, Pfeffer R, Villa S; On behalf of the SIOG Radiotherapy Task Force. Ann Oncol Mar 13.

27 It s about confidence Hospira is one of the major companies producing and marketing biologics globally With 16,000 employees in over 70 countries Hospira Biologics is built on strong foundations of excellence in innovation, service and support. Experienced manufacturer of biologics Hospira Biologics are dedicated to advancing the discovery and development of high-quality pharmaceutical products across a variety of therapy areas. We use our extensive biologics expertise to manufacture our marketed products both in our own facilities and through rigorously evaluated manufacturing partners. Proven efficacy and safety We work hard to ensure our products not only meet stringent efficacy and safety requirements, but also offer the practical features you find useful. Strong heritage Hospira are a global specialty pharmaceutical company with a strong heritage of over 70 years, with access to the resources and skills needed to harness the very latest technological advances in biologics development. Delivering more in everything we do October 2014 EMEA/BIO/14/0007a

28 2015 PRAGUE CZECH REPUBLIC NOV. 15 th Conference of the International Society of Geriatric Oncology "Geriatric Oncology and Supportive Care: a Global Approach to Advance the Science." Save the date!